Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More
Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More
CIPLA | TORRENT PHARMA | CIPLA/ TORRENT PHARMA |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 36.3 | 38.4 | 94.5% | View Chart |
P/BV | x | 4.2 | 9.7 | 43.3% | View Chart |
Dividend Yield | % | 0.5 | 0.6 | 77.5% |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
CIPLA Mar-20 |
TORRENT PHARMA Mar-19 |
CIPLA/ TORRENT PHARMA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 586 | 1,964 | 29.8% | |
Low | Rs | 357 | 1,245 | 28.7% | |
Sales per share (Unadj.) | Rs | 207.0 | 453.4 | 45.7% | |
Earnings per share (Unadj.) | Rs | 18.6 | 25.8 | 72.1% | |
Cash flow per share (Unadj.) | Rs | 33.2 | 62.3 | 53.2% | |
Dividends per share (Unadj.) | Rs | 4.00 | 17.00 | 23.5% | |
Dividend yield (eoy) | % | 0.8 | 1.1 | 80.1% | |
Book value per share (Unadj.) | Rs | 195.5 | 279.2 | 70.0% | |
Shares outstanding (eoy) | m | 806.35 | 169.22 | 476.5% | |
Bonus/Rights/Conversions | ESOS | - | - | ||
Price / Sales ratio | x | 2.3 | 3.5 | 64.3% | |
Avg P/E ratio | x | 25.3 | 62.2 | 40.7% | |
P/CF ratio (eoy) | x | 14.2 | 25.8 | 55.1% | |
Price / Book Value ratio | x | 2.4 | 5.7 | 41.9% | |
Dividend payout | % | 21.5 | 65.9 | 32.6% | |
Avg Mkt Cap | Rs m | 379,912 | 271,513 | 139.9% | |
No. of employees | `000 | 25.8 | 13.6 | 190.1% | |
Total wages/salary | Rs m | 30,270 | 14,038 | 215.6% | |
Avg. sales/employee | Rs Th | 6,459.6 | 5,642.6 | 114.5% | |
Avg. wages/employee | Rs Th | 1,171.2 | 1,032.4 | 113.5% | |
Avg. net profit/employee | Rs Th | 580.2 | 320.9 | 180.8% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 166,949 | 76,728 | 217.6% | |
Other income | Rs m | 3,442 | 571 | 603.3% | |
Total revenues | Rs m | 170,391 | 77,299 | 220.4% | |
Gross profit | Rs m | 32,060 | 19,831 | 161.7% | |
Depreciation | Rs m | 11,747 | 6,177 | 190.2% | |
Interest | Rs m | 1,974 | 5,038 | 39.2% | |
Profit before tax | Rs m | 21,782 | 9,187 | 237.1% | |
Minority Interest | Rs m | -475 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | -3,570 | 0.0% | |
Tax | Rs m | 6,312 | 1,254 | 503.6% | |
Profit after tax | Rs m | 14,995 | 4,363 | 343.7% | |
Gross profit margin | % | 19.2 | 25.8 | 74.3% | |
Effective tax rate | % | 29.0 | 13.6 | 212.4% | |
Net profit margin | % | 9.0 | 5.7 | 158.0% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 117,038 | 50,375 | 232.3% | |
Current liabilities | Rs m | 43,931 | 51,653 | 85.1% | |
Net working cap to sales | % | 43.8 | -1.7 | -2,629.5% | |
Current ratio | x | 2.7 | 1.0 | 273.2% | |
Inventory Days | Days | 96 | 92 | 104.0% | |
Debtors Days | Days | 85 | 68 | 124.6% | |
Net fixed assets | Rs m | 107,424 | 83,648 | 128.4% | |
Share capital | Rs m | 1,613 | 846 | 190.6% | |
"Free" reserves | Rs m | 156,018 | 46,397 | 336.3% | |
Net worth | Rs m | 157,630 | 47,244 | 333.7% | |
Long term debt | Rs m | 23,693 | 39,129 | 60.6% | |
Total assets | Rs m | 236,626 | 141,209 | 167.6% | |
Interest coverage | x | 12.0 | 2.8 | 426.3% | |
Debt to equity ratio | x | 0.2 | 0.8 | 18.1% | |
Sales to assets ratio | x | 0.7 | 0.5 | 129.8% | |
Return on assets | % | 7.2 | 6.7 | 107.7% | |
Return on equity | % | 9.5 | 9.2 | 103.0% | |
Return on capital | % | 12.8 | 12.3 | 104.1% | |
Exports to sales | % | 33.0 | 0 | - | |
Imports to sales | % | 0 | 0 | - | |
Exports (fob) | Rs m | 55,175 | NA | - | |
Imports (cif) | Rs m | NA | NA | - | |
Fx inflow | Rs m | 56,036 | 22,103 | 253.5% | |
Fx outflow | Rs m | 6,764 | 5,522 | 122.5% | |
Net fx | Rs m | 49,272 | 16,581 | 297.2% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 30,685 | 17,981 | 170.7% | |
From Investments | Rs m | 1,040 | -2,413 | -43.1% | |
From Financial Activity | Rs m | -29,488 | -13,145 | 224.3% | |
Net Cashflow | Rs m | 2,340 | 2,380 | 98.3% |
Indian Promoters | % | 16.0 | 71.5 | 22.4% | |
Foreign collaborators | % | 20.8 | 0.0 | - | |
Indian inst/Mut Fund | % | 12.2 | 7.0 | 173.8% | |
FIIs | % | 23.7 | 12.6 | 188.1% | |
ADR/GDR | % | 1.1 | 0.0 | - | |
Free float | % | 26.2 | 8.8 | 297.7% | |
Shareholders | 161,166 | 26,511 | 607.9% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare CIPLA With: GLENMARK PHARMA FULFORD INDIA ORCHID PHARMA AJANTA PHARMA UNICHEM LAB
Compare CIPLA With: ACTAVIS (US) MYLAN (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Indian share markets witnessed heavy selling pressure today, pausing the record rally, with all sectors barring telecom, reeling under pressure.
Here's an analysis of the annual report of CIPLA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.
For the quarter ended September 2020, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 27.0% YoY). Sales on the other hand came in at Rs 20 bn (up 0.6% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.
For the quarter ended June 2020, CIPLA has posted a net profit of Rs 6 bn (up 21.4% YoY). Sales on the other hand came in at Rs 43 bn (up 7.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.
For the quarter ended June 2020, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 48.6% YoY). Sales on the other hand came in at Rs 21 bn (up 1.7% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.
For the quarter ended March 2020, CIPLA has posted a net profit of Rs 2 bn (down 35.1% YoY). Sales on the other hand came in at Rs 44 bn (down 0.6% YoY). Read on for a complete analysis of CIPLA's quarterly results.
More Views on NewsMy new guide will show you the huge potential in future proof businesses.
The smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.
The charts are telling the bulls to be cautious.
Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...
Ajit Dayal on the investing strategy for 2021 and beyond.
More